A sponge you swallow could detect esophageal cancer before it spreads

NCT ID NCT05028725

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests a new way to spot esophageal cancer early using a swallowable sponge called EsophaCap, which collects cells from the esophagus. A lab test then looks for DNA changes linked to cancer. The study enrolls adults with or suspected of having esophageal cancer, as well as healthy controls, to see how accurate the method is. If it works, it could lead to a simple, low-cost screening tool for high-risk areas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a swallowable sponge (EsophaCap) and a DNA methylation biomarker test (EsoCAN assay)
What this could lead to
If successful, this could offer a simple, non-invasive screening method to catch esophageal cancer early, potentially saving lives in regions where the disease is common.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough in larger populations, and false positives or negatives could limit its usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Muhimbili National Hospital (MNH)

    RECRUITING

    Dar es Salaam, Mloganzila, Tanzania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Muhimbili National Hospital (MNH)

    RECRUITING

    Dar es Salaam, Upganda, Tanzania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.